Clinical Trials Browser

Ependymoma × Nivolumab × Clear all

NCT06639607 2026-03-10

PRiME II

Phase 1/2 Not yet recruiting

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Phase 1 Withdrawn

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

NCT07031765 2025-12-18

Peds CHAMP1ON

Phase 1 Active not recruiting

Astrocytoma, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma

NCT03173950 2025-06-29

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Phase 2 Completed

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningioma, Pinealoma, Spinal Cord Neoplasms, Choroid Plexus Neoplasms

NCT04730349 2023-03-24

PIVOT IO 020

Phase 1/2 Terminated

15 enrolled 14 charts

CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell